ImmuPharma PLC Total Liabilities
ImmuPharma PLC total liabilities. Based on the latest financial reports, ImmuPharma PLC (IMM) has total liabilities worth GBX1.24 Million GBX (≈ $151.37 USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check asset resilience ratio of ImmuPharma PLC to evaluate the company's liquid asset resilience ratio.
Total Liabilities of ImmuPharma PLC (2004–2024)
Total liabilities of ImmuPharma PLC from 2004 to 2024. This chart illustrates how ImmuPharma PLC's total liabilities have evolved over time, based on quarterly financial data. Explore ImmuPharma PLC long-term investment intensity to see how much of total assets are deployed in long-term investments.
ImmuPharma PLC Competitors by Total Liabilities
The table below lists competitors of ImmuPharma PLC ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Aquila Energy Efficiency Trust PLC
LSE:AEET
|
UK | GBX991.00K |
|
Global PVQ SE
HM:QCE
|
Germany | €1.18 Billion |
|
Empresaria Group plc
LSE:EMR
|
UK | GBX70.50 Million |
|
Premier Health of America Inc
V:PHA
|
Canada | CA$56.43 Million |
|
Realfiction Holding AB
ST:REALFI
|
Sweden | Skr26.44 Million |
|
Tan Delta Systems PLC
LSE:TAND
|
UK | GBX335.02K |
|
CARLYLE COMMODIT.CORP.
F:BJ4
|
Germany | €342.77K |
Liability Composition Analysis (2004–2024)
This chart breaks down ImmuPharma PLC's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see IMM total asset value.
Liquidity & Leverage Metrics
ImmuPharma PLC Total Liabilities Ratios Explained
ImmuPharma PLC total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.21 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 3.69 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.79 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how ImmuPharma PLC's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for ImmuPharma PLC (2004–2024)
The table below shows the annual total liabilities of ImmuPharma PLC from 2004 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | GBX1.52 Million ≈ $184.92 |
-8.72% |
| 2023-12-31 | GBX1.67 Million ≈ $202.60 |
+14.73% |
| 2022-12-31 | GBX1.45 Million ≈ $176.58 |
-8.39% |
| 2021-12-31 | GBX1.58 Million ≈ $192.76 |
+25.65% |
| 2020-12-31 | GBX1.26 Million ≈ $153.41 |
+137.07% |
| 2019-12-31 | GBX531.87K ≈ $64.71 |
-48.60% |
| 2018-12-31 | GBX1.03 Million ≈ $125.90 |
-28.28% |
| 2017-12-31 | GBX1.44 Million ≈ $175.54 |
+23.97% |
| 2016-12-31 | GBX1.16 Million ≈ $141.60 |
-23.57% |
| 2015-12-31 | GBX1.52 Million ≈ $185.26 |
+11.39% |
| 2014-12-31 | GBX1.37 Million ≈ $166.32 |
-24.12% |
| 2013-12-31 | GBX1.80 Million ≈ $219.19 |
-13.87% |
| 2012-12-31 | GBX2.09 Million ≈ $254.48 |
+17.97% |
| 2011-12-31 | GBX1.77 Million ≈ $215.72 |
+12.07% |
| 2010-12-31 | GBX1.58 Million ≈ $192.48 |
-75.88% |
| 2009-12-31 | GBX6.56 Million ≈ $798.16 |
+203.42% |
| 2008-12-31 | GBX2.16 Million ≈ $263.05 |
+105.90% |
| 2007-12-31 | GBX1.05 Million ≈ $127.75 |
-27.03% |
| 2006-12-31 | GBX1.44 Million ≈ $175.08 |
+28.14% |
| 2006-03-31 | GBX1.12 Million ≈ $136.64 |
+7921.43% |
| 2005-03-31 | GBX14.00K ≈ $1.70 |
+600.00% |
| 2004-03-31 | GBX2.00K ≈ $0.24 |
-- |
About ImmuPharma PLC
ImmuPharma plc, a biopharmaceutical company, discovers and develops peptide-based therapeutics in the United Kingdom. Its peptide-based therapeutics focuses on autoimmunity and inflammation, and anti-infectives therapeutic areas. The company's lead product candidate includes P140, a peptide technology platform, which is in Phase III clinical trial that targets autoimmune diseases for systemic lup… Read more